We evaluated spray-dried animal plasma (SDAP) as an alternative to antimicrobial medication with colistin sulfate in weanling pigs challenged with Escherichia coli K99. Forty-eight piglets weaned at 24 d of age were distributed into 12 pens, and each pen was assigned to one of four dietary treatments. All the piglets were given an oral dose of 5 × 10 7 cfu of E. coli K99 at weaning. The dietary treatments followed a factorial arrangement with two levels of SDAP (0 and 7%) and two levels of colistin (0 and 300 mg/kg of diet). The ADG and ADFI were measured on d 7 and 14 of trial. Three piglets from each treatment were killed on d 7 and 14 to remove the small intestine, and to obtain ileal and cecal digestive contents. The inclusion of SDAP improved ADG by 68 g (P < 0.05) and ADFI by 41 g (P < 0.10) in wk 1 of trial. During wk 2, SDAP improved ADG by 41 g (P < 0.10) and gain:feed ratio (G:F) by 25% (P < 0.01). On the other hand, whereas colistin had no effect on performance in wk 1, it improved ADG by 102 g (P < 0.01), ADFI by 62 g (P < 0.01), and G:F by 26% (P < 0.01) in wk 2. Over the 14 d of the trial, ADG was improved by 54 (P < 0.05) and
Leclercia adecarboxylata (LAD) is a member of Enterobacteriaceae family that is usually reported as an opportunistic human pathogen. A few reports have described resistant strains in the literature. The aim of this paper was to describe the antimicrobial resistance pattern of a LAD strain isolated from a urinary tract infection in a 39-year-old immunocompetent man. The bacterial identification and antibiotic sensitivity tests were performed on Vitek 2 Compact 15. The results revealed the presence of LAD with a particular multidrug resistance pattern. It was sensitive only to imipenem (=1 µg/ml), and totally resistant to association of trimethoprim/sulfamethoxazole (≥320 µg/ml), ticarcillin (≥128 µg/ml), nitrofurantoin (=128 µg/ml), cefalothin (≥64 µg/ml), cefoxitin (≥64 µg/ml), cefotaxime (≥64 µg/ml), ceftazidime (≥64 µg/ml), amikacin (≥64 µg/ml), ampicillin (≥32 µg/ml), nalidxic acid (≥32 µg/ml), and a combination of amoxicillin/clavulanic acid (≥32 µg/ml), gentamicin (≥16 µg/ml), tobramycin (≥16 µg/ml), ofloxacin (≥8 µg/ml), and ciprofloxacin (≥4 µg/ml). It showed the intermediate sensitivity to the association of piperacillin/tazobactam (=64 µg/ml), and ertapenem (=4 µg/ml). The findings showed that this isolate of LAD had a multidrug resistance pattern to almost all the antibiotics tested (except imipenem). This suggests that LAD could be considered as an emergent bacterial pathogen capable of causing infections in human and carrying multidrug resistance pattern to numerous antibiotic families in Guinea.
Introduction : Les infections à Pseudomonas constituent un réel problème de santé publique mondiale.L'objectif de cette étude était de déterminer les espèces de Pseudomonas isolées de diverses secrétionsbiologiques ainsi que leur sensibilité aux antibiotiques. Matériel et méthodes : Il s'agit d'une étuderétrospective réalisée à l'Hôpital de l'Amitié Sino-Guinéenne de Juin 2014 à Juin 2018. Les cultures ont étéfaites sur milieux gélosés. L'identification bactérienne, les antibiogrammes et la détermination desconcentrations minimales inhibitrices (CMI) ont été faites à l'automate Vitek2 Compact 15. Résultats :Soixante-quinze souches de Pseudomonas ont été identifiées : Pseudomonas aeruginosa (44), de Pseudomonasluteola (15), Pseudomonas fluorescens (13), Pseudomonas mendocina (1), Pseudomonas oryzihabitans (1) etPseudomonas putida (1). L'âge moyen des patients était de 49,12±23,48 ans [18 jours-90 ans]. Le sexe-ratio(M/F) = 0,875. La majorité des souches étaient sensibles à l'imipénème (93,33%), l'amikacine (88,00%), lagentamicine (72,00%), la tobramycine (70,66%), piperacilline/tazobactam (70,66%), la ceftazidime (60,00%),céfotaxime (54,66%), à l'ofloxacine (57,33%) et la ciprofloxacine (58,66%). En revanche, ces souches étaientrésistantes à l'ampicilline (89,33%), triméthoprime/sulfaméthoxazole (89,33%), l'acide nalidixique (85,33%), lacéfalotine (77,33%), la ticarcilline (68,00%), la cefoxitine (64,00%), et la nitrofurantoine (57,33%). Des cas demulti-résistance aux antibiotiques ont été observés avec CMI élevées. Particulièrement, une souche dePseudomonas aeruginosa désignée N°64 était multi-résistante à tous les d'antibiotiques testés. Conclusion : Sixespèces de Pseudomonas ont été identifiées avec des phénotypes de multi-résistance aux antibiotiqueshabituellement utilisés en Guinée.
Introduction: Escherichia coli (E. coli) is one of the main bacterial species associated with urinary tract infections. Nowadays, this bacterium is becoming more and more resistant to antibiotics. Objective: The aim of this study was to determine the antibiotic sensitivity profiles of all strains of E. coli isolated from urine during the period from September 1st, 2018 to March 13th, 2019 at the Biomedical Laboratory of the China-Guinea Friendship Hospital of Kipé in Conakry. Materiel and Methods: Cultures were done on different agar media. Bacterial identification, antibiograms and determination of minimum inhibitory concentrations (MIC) were performed on the Vitek 2 Compact 15 automated system. Results: A total of 66 strains of E. coli have been isolated from patients of both sexes. The sex ratio (M/F) was 0.43. The mean age of the patients was 50.83 years. The majority of strains were sensitive to imipenem (96.96%), amikacin (96.96%), ertapenem (94.73%), gentamicin (69.23%), tobramycin (60, 60%), cefoxitin (64.28%), cefotaxime (62.50%), piperacillin/tazobactam (77.4%), amoxicillin/clavulanic acid (50.00%) and nitrofurantoin (87%). In contrast, the majority of strains were resistant to ampicillin (81.81%), cefalotin (62.02%), ticarcillin (88.00%), nalidixic acid (82.75%), ciprofloxacin (56.06%), ofloxacin (56.00%) and combination of trimethoprim/sulfamethoxazole (83.60%), sometimes with high MICs. Conclusion: Our results show that urinary tract infections due to E. coli are more frequently observed in females than in males. Some of these strains studied exhibited multidrug resistance profiles to antibiotics. Among the classes of antibiotics tested, carbapenemes, nitrofurans, aminoglycosides, appear to be more active on E. coli uropathogenes in Guinea.
Introduction: Diarrheal infections associated to multidrug resistant bacteria are a public health problem, particularly in the tropics. Objective: The aim of this study was to describe a Multidrug resistant strain of Escherichia coli (E. coli) isolated from diarrheal stools. Patients and methods: A sample of diarrheal stools from a 30 years old housekeeper patient was analysed at China-Guinea Friendship Hospital of Kipé/Conakry. Parasitological examination by optical microscopy, followed by bacteriological analysis were done. Cultures were carried out on different agar media. Bacterial identification, antibiograms and minimum inhibitory concentrations (MIC) were performed using the Vitek 2 System. Results: The isolated E. coli strain was sensitive only to 4 of 29 antibiotics tested including imipenem, ertapenem, amikacin and nitrofurantoin. Intermediate sensitivity was detected towards minocycline. In contrast, this strain was resistant to piperacillin, cefuroxime, cefuroxime axetil, cefixime, ceftriaxone, cefepime, aztreonam, meropenem, levofloxacin, ofloxacin, tetracycline, tigecycline, chloramphenicol, trimethoprim, ampicillin, amoxicillin/clavulanic acid, ticarcillin, piperacillin/tazobactam, cephalothin, cefotaxime, ceftazidime, gentamicin, tobramycin, nalidixic acid, ciprofloxacin, ofloxacin and trimethoprim/sulfamethoxazole with high MICs. Conclusion: The treatment of this multidrug-resistant Escherichia coli diarrheal infection requires appropriate antibiotic therapy, based on the results of an accurate antibiogram to be performed with rapid means for better patient care.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.